TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02805400

Intervention type: OTHER
Group type: OTHER
Intervention: determination of cortical activity
Description: Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used.
Study: NCT04152434

Intervention type: DRUG
Intervention: Erenumab Auto-Injector
Description: Assess synergy of add on medication to Erenumab

Intervention type: DRUG
Intervention: Erenumab Auto-Injector
Description: Assess synergy of add on medication to Erenumab

Intervention type: DRUG
Intervention: Erenumab Auto-Injector
Description: Assess synergy of add on medication to Erenumab
Study: NCT02181335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03639064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Oil
Description: Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Oil
Description: Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Oil
Description: Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil.
Study: NCT04384991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU007
Description: Cyclosporine 0.02% with Trehalose 3%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis eye drop
Description: Cyclosporine 0.05%
Study: NCT03606889

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block
Description: 0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
Study: NCT02031224

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional low protein diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very low protein diet supplemented with Ketosteril
Study: NCT01030185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaShunt's Automated Fluid Shunt implantation
Description: The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
Study: NCT02691403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levo-bupivacaine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Study: NCT01561547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care
Description: Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care
Description: Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
Study: NCT01333995

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Peer counseling on infant feeding
Description: Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
Study: NCT02443909

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser device
Study: NCT01724424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 20 mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 30 mg oral single dose
Study: NCT02443909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser device
Study: NCT05863169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fNIRS-Neurofeedback
Description: Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2\*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
Study: NCT01004744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg PO daily for two weeks prior to scheduled surgery
Study: NCT02988921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, platinum-based drug
Study: NCT01073709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study: NCT01724424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 50mg oral single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 100mg oral single dose
Study: NCT01073709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Study: NCT00267046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 180 mcg/kg 3 days prior to chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose 3 days prior to chemotherapy
Study: NCT02262104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive exercise
Description: Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
Study: NCT01706042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: legume meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: white bread
Study: NCT00442091

Intervention type: DRUG
Group type: OTHER
Intervention: dandelion juice
Description: 10 ml bid for 20-30 days
Study: NCT00393341

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood sample will be drawn from a vein in the arm.

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood sample will be drawn from a vein in the arm.
Study: NCT03790800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urapidil
Description: A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.
Study: NCT00086502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Sitagliptin
Description: Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
Study: NCT03585920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Corn Snack
Description: A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expanded Corn Snack
Description: A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Corn Snack
Description: A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
Study: NCT03364842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Administering furosemide
Study: NCT02498028

Intervention type: PROCEDURE
Intervention: Cervical Fusion
Description: Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)

Intervention type: PROCEDURE
Intervention: Cervical disc Prostheses
Description: The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
Study: NCT04770675

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: All subjects who are scheduled for a bronchoscopy may be eligible.
Study: NCT00086502

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Pioglitazone
Description: Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
Study: NCT05456230

Intervention type: DRUG
Intervention: Midazolam
Description: Midazolam as a premedication was given as the patient is taken to the operating room and typically within 15 minutes of anesthetic induction.
Study: NCT04584762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Variable Pressure Insufflation
Description: Acute migraine treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Automated Variable Pressure Insufflation
Description: Acute migraine treatment
Study: NCT00086502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Pioglitazone
Description: Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8
Study: NCT04810936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplements
Description: Oral nutritional supplements is usually administrated to improve nutritional status in cancer patients.
Study: NCT03490149

Intervention type: DEVICE
Intervention: Electroconvulsive Therapy
Description: Series of electroconvulsive therapy for major depressive disorder

Intervention type: DRUG
Intervention: Medication - Treatment as usual
Description: Medication only sample - Treatment as usual
Study: NCT01304329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Medium dose oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Medium dose oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Medium dose oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: Medium dose oral administration
Study: NCT02183129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Study: NCT01592617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-488410
Description: In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
Study: NCT04101617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Health education including printed educational material
Description: Printed and online educational materials were developed and provided to pediatricians so they can share relevant information about caries control to parents of toddlers. A previous interview was performed to pediatricians as focus groups to know how they are doing their evaluations and what do they take into account during the children visits in order to identify where to focus for the training what it is necessary to change. After that pediatricians were trained to give oral health recommendations. So, to the intervention group, the pediatricians will give these recommendations to the parents and also they will give them a printed educational material previously developed for the project.
Study: NCT04053595

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic parameters of fluid responsiveness protocol
Description: Dynamic parameter of fluid responsiveness (pulse pressure variation/stroke volume variation) are used to optimize hemodynamics intraoperatively and during the first 6 hours postoperatively when appropriate. A cutoff of 12% is used to predict an increase of stroke volume \>10% after fluid administration.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Estimated oxygen extraction protocol
Description: Oxygen extraction is estimated by the difference of arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation. A cutoff of 27% is used as a marker of inadequate tissue perfusion requiring hemodynamic optimization.
Study: NCT02809755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Lidocaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00754325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 100 mg, once daily (QD), upto 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
Study: NCT03606889

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tranversus Abdominis plane block
Description: 0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.2 ml/kg bupivicaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.2 ml/kg bupivicaine
Study: NCT03996525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~1. Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~2. Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Treatment
Description: Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~1. Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~2. Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision.
Study: NCT01813149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine and clonidine
Description: Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: punch biopsy
Study: NCT01885962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSHIFTup
Description: Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
Study: NCT02706561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: three in-person sessions
Study: NCT00396812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.~Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid.
Study: NCT00242632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namenda
Description: Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namenda
Description: Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
Study: NCT02753920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: voiding trial
Description: 1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: voiding trial
Description: 1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
Study: NCT02706561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: three in-person sessions
Study: NCT02753920

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
Study: NCT03776916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simethicone administration 20-30 min before the procedure
Description: Patients intake simethicone 20-30 min before the procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simethicone administration 31-60 min before the procedure
Description: Patients intake simethicone administration 31-60 min before the procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simethicone administration > 60 min before the procedure
Description: Patients intake simethicone administration \> 60 min before the procedure.
Study: NCT02706561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: monthly phone calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: monthly phone calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Monitoring and Education (EME)
Study: NCT04266470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lara Scan
Description: Four (4) sensors will be placed prior to the injection of 18 F-fludeoxyglucose (18FDG) at the following sites: 7 cm above injection site; injection site; surface of palpable presumed malignant tissue; palpable carotid artery.~Standard doses of 18-FDG will be injected per Department of Radiology protocols~All injections will be evaluated to insure the total dose of 18-FDG has been injected. Injections resulting in moderate to severe extravasations, as interpreted by Lara software, will be segregated and evaluated on an individual basis.~The sensors will remain in place for 60 minutes during the 18-FDG uptake period with the patient in a reclined chair.~After the uptake time is complete, the sensors will be removed by the technologist and the participant will be released.~The study team will then upload the sensor data to a personal computer in the treatment planning room where it will be coded and processed as a Lara scan.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Scan - Pre-treatment and Post-treatment
Description: The PET/CT imaging will be conducted according to standard of care. The main alteration to process flow will be the addition of the Lucerno sensors just prior to the injection of the PET material.